Intevac Announces Second Quarter 2014 Financial Results
Mon, July 28 2014
“During the second quarter, our Photonics business achieved
record levels of both revenue and operating profit and is on track to
grow by approximately 30% this year as compared to 2013,” commented
"In our thin film equipment business, we are on track to ship our first protective coating system for touch screen mobile cover glass, as well as our first INTEVAC MATRIX™ PVD system for solar cell manufacturing, within the next few weeks. Each of these deployments demonstrates meaningful progress on our strategy to provide thin film deposition systems to vacuum coating markets adjacent to the hard disk media industry. The hard drive industry is predicting improving demand through the second half of the year, and industry analysts are forecasting annual sequential growth in media units beginning in 2014.”
($ Millions, except per share amounts) | Q2 2014 | Q2 2013 | ||||||||||||||||||||
GAAP Results | Non-GAAP Results | GAAP Results | Non-GAAP Results | |||||||||||||||||||
Net Revenues | $ | 14.7 | $ | 14.7 | $ | 17.0 | $ | 17.0 | ||||||||||||||
Operating Loss | $ | (5.2 | ) | $ | (5.1 | ) | $ | (7.0 | ) | $ | (7.1 | ) | ||||||||||
Net Loss | $ | (5.0 | ) | $ | (4.9 | ) | $ | (6.4 | ) | $ | (6.5 | ) | ||||||||||
Net Loss per Share | $ | (0.21 | ) | $ | (0.20 | ) | $ | (0.27 | ) | $ | (0.27 | ) | ||||||||||
Six Months Ended | Six Months Ended | |||||||||||||||||||||
|
|
|||||||||||||||||||||
GAAP Results | Non-GAAP Results | GAAP Results | Non-GAAP Results | |||||||||||||||||||
Net Revenues | $ | 31.7 | $ | 31.7 | $ | 30.0 | $ | 30.0 | ||||||||||||||
Operating Loss | $ | (10.0 | ) | $ | (9.6 | ) | $ | (16.0 | ) | $ | (15.3 | ) | ||||||||||
Net Loss | $ | (9.5 | ) | $ | (9.1 | ) | $ | (14.7 | ) | $ | (14.0 | ) | ||||||||||
Net Loss per Share | $ | (0.40 | ) | $ | (0.38 | ) | $ | (0.62 | ) | $ | (0.59 | ) | ||||||||||
Intevac’s non-GAAP adjusted results exclude the impact of the following, where applicable: (1) changes in fair value of contingent consideration liabilities associated with business combinations; (2) restructuring charges; and (3) gains or losses on sales of product lines and technology assets. A reconciliation of the GAAP and non-GAAP adjusted results is provided in the financial table included in this release. See also “Use of Non-GAAP Financial Measures” section.
Second Quarter 2014 Summary
The net loss for the quarter was
Revenues were
Equipment gross margin was 8.3% compared to 14.8% in the second quarter of 2013 and 22.2% in the first quarter of 2014. Equipment margins in the second quarter of 2014 were lower due to lower factory absorption as a result of the lower level of revenue. Equipment margins in the second quarter of 2013 reflected a refurbishment reserve recorded for a solar evaluation system as well as the lower margin on the first solar implant ENERGi system recognized for revenue.
Photonics gross margin was 44.7% compared to 31.7% in the second quarter of 2013 and 35.2% in the first quarter of 2014. The improvement from the second quarter of 2013 was driven by the increased mix of higher margin product revenue, improved yields for our low-light sensor, and higher margins on technology development programs. The improvement from the first quarter of 2014 was driven by the increased mix of higher margin products, improved yields offset in part by lower margins on technology development programs. Consolidated gross margin was 35.4%, compared to 22.5% in the second quarter of 2013 and 28.3% in the first quarter of 2014.
Operating expenses of
Order backlog totaled
The company ended the quarter with
First Six Months 2014 Summary
The net loss was
Revenues were
Equipment gross margin was 18.1%, compared to 17.6% in the first six months of 2013, primarily due to higher margins from systems, lower factory overhead expenses and lower inventory charges. We recognized revenue on one 200 Lean system in the first half of 2014 and did not recognize any revenue on 200 Lean systems in the first half of 2013. Fiscal 2013 Equipment gross margin reflected a refurbishment provision for a solar evaluation system and the lower system margin on the first solar implant ENERGi system recognized for revenue. Photonics gross margin was 40.7% compared to 31.0% in the first six months of 2013, reflecting the increased mix of higher margin product shipments, improved yields, higher margins on technology development programs and lower warranty costs. Consolidated gross margin was 31.6%, compared to 24.5% in the first six months of 2013.
Operating expenses were
Use of Non-GAAP Financial Measures
Management uses non-GAAP results to evaluate the company’s operating and
financial performance in light of business objectives and for planning
purposes. These measures are not in accordance with GAAP and may differ
from non-GAAP methods of accounting and reporting used by other
companies.
Conference Call Information
The company will discuss its financial results and outlook in a conference call today at 1:30 p.m. PDT (4:30 p.m. EDT). To participate in the teleconference, please call toll-free (877) 334-0811 prior to the start time. For international callers, the dial-in number is (408) 427-3734. You may also listen live via the Internet at the company's website, www.intevac.com, under the Investors link, or at www.earnings.com. For those unable to attend, these web sites will host an archive of the call. Additionally, a telephone replay of the call will be available for 48 hours beginning today at 7:30 p.m. EDT. You may access the replay by calling (855) 859-2056 or, for international callers, (404) 537-3406, and providing Replay Passcode 69076711.
About
In our Equipment business, we are a leader in the design and development of high-productivity, thin film processing systems. Our production-proven platforms are designed for high-volume manufacturing of substrates with precise thin film properties.
In our Photonics business, we are a recognized leading developer of advanced high-sensitivity digital sensors, cameras and systems that primarily serve the defense industry. We are the sole-source provider of integrated digital imaging systems for most U.S. military night vision programs.
For more information call 408-986-9888, or visit the company's website at www.intevac.com.
200 Lean® is a registered trademark and
Safe Harbor Statement
This press release includes statements that constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “Reform Act”).
|
|||||||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||||||
(Unaudited, in thousands, except per share amounts) |
|||||||||||||||||||||
Three months ended | Six months ended | ||||||||||||||||||||
|
|
|
|
||||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||||
Net revenues | |||||||||||||||||||||
Equipment |
$ | 3,762 | $ | 9,164 | $ | 12,809 | $ | 14,532 | |||||||||||||
Photonics | 10,953 | 7,819 | 18,921 | 15,433 | |||||||||||||||||
Total net revenues | 14,715 | 16,983 | 31,730 | 29,965 | |||||||||||||||||
Gross profit | 5,211 | 3,829 | 10,021 | 7,343 | |||||||||||||||||
Gross margin | |||||||||||||||||||||
Equipment | 8.3 | % | 14.8 | % | 18.1 | % | 17.6 | % | |||||||||||||
Photonics | 44.7 | % | 31.7 | % | 40.7 | % | 31.0 | % | |||||||||||||
Consolidated | 35.4 | % | 22.5 | % | 31.6 | % | 24.5 | % | |||||||||||||
Operating expenses | |||||||||||||||||||||
Research and development | 4,558 | 5,584 | 8,831 | 11,943 | |||||||||||||||||
Selling, general and administrative | 5,853 | 5,555 | 11,063 | 11,415 | |||||||||||||||||
Acquisition-related1 | 46 | (320 | ) | 97 | (209 | ) | |||||||||||||||
Total operating expenses | 10,457 | 10,819 | 19,991 | 23,149 | |||||||||||||||||
Loss on divestiture2 |
— | — | — | (208 | ) | ||||||||||||||||
Total operating loss | (5,246 | ) | (6,990 | ) | (9,970 | ) | (16,014 | ) | |||||||||||||
Income/(Loss) from operations | |||||||||||||||||||||
Equipment | (5,667 | ) | (5,841 | ) | (9,808 | ) | (13,183 | ) | |||||||||||||
Photonics | 2,567 | 253 | 3,475 | 62 | |||||||||||||||||
Corporate2 | (2,146 | ) | (1,402 | ) | (3,637 | ) | (2,893 | ) | |||||||||||||
Total operating loss | (5,246 | ) | (6,990 | ) | (9,970 | ) | (16,014 | ) | |||||||||||||
Interest and other income | 120 | 92 | 192 | 172 | |||||||||||||||||
Loss before income taxes | (5,126 | ) | (6,898 | ) | (9,778 | ) | (15,842 | ) | |||||||||||||
Benefit from income taxes | (119 | ) | (486 | ) | (250 | ) | (1,166 | ) | |||||||||||||
Net loss | $ | (5,007 | ) | $ | (6,412 | ) | $ | (9,528 | ) | $ | (14,676 | ) | |||||||||
Loss per share | |||||||||||||||||||||
Basic and Diluted | $ | (0.21 | ) | $ | (0.27 | ) | $ | (0.40 | ) | $ | (0.62 | ) | |||||||||
Weighted average common shares outstanding | |||||||||||||||||||||
Basic and Diluted | 23,927 | 23,785 | 23,892 | 23,724 | |||||||||||||||||
1Results for all periods presented include changes in fair
value of contingent consideration obligations associated with the Solar
Implant Technology (SIT) acquisition in 2010.
2Six
months ended June 29, 2013 includes the loss on sale of the Raman
spectroscopy product line of
|
|||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||
(In thousands, except par value) |
|||||||||||
|
|||||||||||
|
2013 | ||||||||||
(Unaudited) | (see Note) | ||||||||||
ASSETS | |||||||||||
Current assets | |||||||||||
Cash, cash equivalents and short-term investments | $ | 58,232 | $ | 69,096 | |||||||
Accounts receivable, net | 9,265 | 15,037 | |||||||||
Inventories | 22,613 | 22,762 | |||||||||
Prepaid expenses and other current assets | 1,443 | 1,237 | |||||||||
Total current assets | 91,553 | 108,132 | |||||||||
Long-term investments | 17,064 | 12,318 | |||||||||
Restricted cash | 1,000 | — | |||||||||
Property, plant and equipment, net | 13,316 | 12,945 | |||||||||
Deferred income tax assets | 9,818 | 9,502 | |||||||||
Intangible assets, net | 4,434 | 4,902 | |||||||||
Other long-term assets | 55 | 477 | |||||||||
Total assets | $ | 137,240 | $ | 148,276 | |||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities | |||||||||||
Accounts payable | $ | 4,256 | $ | 4,011 | |||||||
Accrued payroll and related liabilities | 4,237 | 5,034 | |||||||||
Deferred income tax liabilities | 939 | 939 | |||||||||
Other accrued liabilities | 2,836 | 3,263 | |||||||||
Customer advances | 2,114 | 3,743 | |||||||||
Total current liabilities | 14,382 | 16,990 | |||||||||
Other long-term liabilities | 2,175 | 1,715 | |||||||||
Stockholders’ equity | |||||||||||
Common stock ( |
24 | 24 | |||||||||
Additional paid in capital | 158,490 | 156,359 | |||||||||
Treasury stock, at cost | (3,157 | ) | (1,688 | ) | |||||||
Accumulated other comprehensive income | 703 | 725 | |||||||||
Accumulated deficit | (35,377 | ) | (25,849 | ) | |||||||
Total stockholders’ equity | 120,683 | 129,571 | |||||||||
Total liabilities and stockholders’ equity | $ | 137,240 | $ | 148,276 | |||||||
Note: Amounts as of December 31, 2013 are derived from the December 31, 2013 audited consolidated financial statements.
|
|||||||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP RESULTS | |||||||||||||||||||
(Unaudited, in thousands, except per share amounts) |
|||||||||||||||||||
Three months ended | Six months ended | ||||||||||||||||||
|
|
|
|
||||||||||||||||
2014 | 2013 | 2014 | 2013 | ||||||||||||||||
Non-GAAP Loss from Operations | |||||||||||||||||||
Reported operating loss (GAAP basis) | $ | (5,246 | ) | $ | (6,990 | ) | $ | (9,970 | ) | $ | (16,014 | ) | |||||||
Restructuring charges1 | 61 | 240 | 288 | 742 | |||||||||||||||
Change in fair value of contingent consideration obligations2 | 46 | (320 | ) | 97 | (209 | ) | |||||||||||||
Loss on sale of Raman spectroscopy product line3 | — | — | — | 208 | |||||||||||||||
Non-GAAP Operating Loss | $ | (5,139 | ) | $ | (7,070 | ) | $ | (9,585 | ) | $ | (15,273 | ) | |||||||
Non-GAAP Net Loss | |||||||||||||||||||
Reported net loss (GAAP basis) | $ | (5,007 | ) | $ | (6,412 | ) | $ | (9,528 | ) | $ | (14,676 | ) | |||||||
Restructuring charges1 | 61 | 240 | 288 | 742 | |||||||||||||||
Change in fair value of contingent consideration obligations2 | 46 | (320 | ) | 97 | (209 | ) | |||||||||||||
Loss on sale of Raman spectroscopy product line3 | — | — | — | 208 | |||||||||||||||
Income tax effect of non-GAAP adjustments4 | — | (20 | ) | — | (42 | ) | |||||||||||||
Non-GAAP Net Loss | $ | (4,900 | ) | $ | (6,512 | ) | $ | (9,143 | ) | $ | (13,977 | ) | |||||||
Non-GAAP Loss Per Diluted Share | |||||||||||||||||||
Reported loss per diluted share (GAAP basis) | $ | (0.21 | ) | $ | (0.27 | ) | $ | (0.40 | ) | $ | (0.62 | ) | |||||||
Restructuring charges1 | $ | — | $ | 0.01 | $ | 0.01 | $ | 0.03 | |||||||||||
Change in fair value of contingent consideration obligations2 | $ | — | $ | (0.01 | ) | $ | — | $ | (0.01 | ) | |||||||||
Loss on sale of Raman spectroscopy product line3 | $ | — | $ | — | $ | — | $ | 0.01 | |||||||||||
Non-GAAP Loss Per Diluted Share | $ | (0.20 | ) | $ | (0.27 | ) | $ | (0.38 | ) | $ | (0.59 | ) | |||||||
Weighted average number of diluted shares | 23,927 | 23,785 | 23,892 | 23,724 | |||||||||||||||
1Results for all periods presented include severance and other employee-related costs related to various restructuring programs.
2Results for all periods presented include changes in fair value of contingent consideration obligations associated with the Solar Implant Technology (SIT) acquisition in 2010.
3The six months ended June 29, 2013 includes the loss on sale
of the Raman spectroscopy product line of
4The amount represents the estimated income tax effect of the non-GAAP adjustments. The Company calculated the tax effect of non-GAAP adjustments by applying an applicable estimated jurisdictional tax rate to each specific non-GAAP item.
Chief Financial
Officer
Investor Relations
Source: